Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>QIAGEN N.V. reported preliminary results for the first quarter of 2026, revealing a mixed performance marked by solid profitability but sales slightly below prior expectations.</li>
<li>The company delivered adjusted diluted earnings per share (EPS) of $0.54 at constant exchange rates (CER), meeting its outlook despite a challenging macroeconomic environment and uneven sales across business segments.</li>
<li>Total net sales were $492 million, representing a 2% increase on a reported basis but a 1% decline at CER, falling short of the targeted minimum 1% CER growth.</li>
</ul>


QIAGEN N.V. reported preliminary results for the first quarter of 2026, revealing a mixed performance marked by solid profitability but sales slightly below prior expectations.
The company delivered adjusted diluted earnings per share (EPS) of $0.54 at constant exchange rates (CER), meeting its outlook despite a challenging macroeconomic environment and uneven sales across business segments.
Total net sales were $492 million, representing a 2% increase on a reported basis but a 1% decline at CER, falling short of the targeted minimum 1% CER growth.


QIAGEN의 전망 재설정: 디지털 PCR 및 샘플 기술이 QuantiFERON의 약점을 상쇄할 수 있을까?

QIAGEN NV

QIAGEN의 전망 재설정: 디지털 PCR 및 샘플 기술이 QuantiFERON의 약점을 상쇄할 수 있을까?